Expression and cytoprotective effect of protease-activated receptor-1 in gastric epithelial cells

被引:1
|
作者
Toyoda, N
Gabazza, EC
Inoue, H
Araki, K
Nakashima, S
Oka, S
Taguchi, Y
Nakamura, M
Suzuki, Y
Taguchi, O
Imoto, I
Suzuki, K
Adachi, Y
机构
[1] Mie Univ, Sch Med, Dept Internal Med 3, Tsu, Mie 5148507, Japan
[2] Mie Univ, Sch Med, Dept Mol Pathobiol, Tsu, Mie 5148507, Japan
关键词
coagulation activation; gastric injury; prostaglandin E2; thrombin receptor;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Thrombin is a serine protease involved in many physiological functions and its receptor, the protease-activated receptor-1 (PAR-1), has a wide tissue distribution. We hypothesized that PAR-1 is expressed in gastric epithelial cells and that thrombin can modulate defence mechanisms through PAR-1. The rat gastric epithelial cell line (RMG1) and gastric biopsy specimens from gastritis patients were used in the study. Reverse transcriptase polymerase chain reaction analysis showed that the thrombin receptors PAR-1, PAR3 and PAR-4 are expressed by RGM1 gastric epithelial cell line. Immunohistochemical and electron microspcopic studies also showed PAR-1 expression in human gastric epithelial cells. Thrombin stimulated the secretion of mucin and prostaglandin E2 (PGE2) formation in RGM1 cells in a dose-dependent manner. PAR-1 agonist also stimulated PGE2 formation. In addition, thrombin significantly increases the expression of the PGE2 receptors EP2-R and EP4-R in RGM1 cells. In conclusion, the results of the present study showed for the first time that gastric epithelial cells express thrombin receptors and that these receptors may play a protective role in the gastric mucosa.
引用
收藏
页码:253 / 259
页数:7
相关论文
共 50 条
  • [1] Protease-activated receptor-1 at the synapse
    Shavit-Stein, E.
    Katzev, A.
    Chapman, J.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2011, 45 (SUPPL 1) : S108 - S108
  • [2] Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects
    Schuepbach, R. A.
    Madon, J.
    Ender, M.
    Galli, P.
    Riewald, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (08) : 1675 - 1684
  • [3] Expression of protease-activated receptor-1 and-2 in orofacial granulomatosis
    Ketabchi, S.
    Massi, D.
    Ficarra, G.
    Rubino, I.
    Franchi, A.
    Paglierani, M.
    Simoni, A.
    Capodiferro, S.
    Favia, G.
    Maiorano, E.
    Tarantini, F.
    Cirino, G.
    Santucci, M.
    ORAL DISEASES, 2007, 13 (04) : 419 - 425
  • [4] Cyclic strain increases protease-activated receptor-1 expression in vascular smooth muscle cells
    Nguyen, KT
    Frye, SR
    Eskin, SG
    Patterson, C
    Runge, MS
    McIntire, LV
    HYPERTENSION, 2001, 38 (05) : 1038 - 1043
  • [5] Regulation of protease-activated receptor-1 and-2 expression on antigen presenting cells by cytokines
    Colognato, R
    Slupsky, JR
    Jendrach, M
    Burysek, L
    Simmet, T
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 363 (04) : R82 - R82
  • [6] Thrombin conducts epithelial-mesenchymal transition via protease-activated receptor-1 in human gastric cancer
    Otsuki, Tadayoshi
    Fujimoto, Daisuke
    Hirono, Yasuo
    Goi, Takanori
    Yamaguchi, Akio
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (06) : 2287 - 2294
  • [7] Role of Protease-Activated Receptor-1 in Glioma Growth
    Xie, Qing
    Bao, Xuhui
    Chen, Zhan Hong
    Xu, Ying
    Keep, Richard F.
    Muraszko, Karin M.
    Xi, Guohua
    Hua, Ya
    BRAIN EDEMA XVI: TRANSLATE BASIC SCIENCE INTO CLINICAL PRACTICE, 2016, 121 : 355 - 360
  • [8] Vorapaxar: a novel protease-activated receptor-1 inhibitor
    Gurbel, Paul A.
    Jeong, Young-Hoon
    Tantry, Udaya S.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (10) : 1445 - 1453
  • [9] The role of protease-activated receptor-1 in bone healing
    Song, SJ
    Pagel, CN
    Campbell, TM
    Pike, RN
    Mackie, EJ
    AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (03): : 857 - 868
  • [10] Therapeutic potential of protease-activated receptor-1 antagonists
    Derian, CK
    Maryanoff, BE
    Zhang, HC
    Andrade-Gordon, P
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (02) : 209 - 221